Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesMyeloproliferative Diseases and Disorders, Poorly Differentiated NeoplasmsDRG 839-chemotherapy-with-acute-leukemia-as-secondary-diagnosis-without-cc-mcc
    Ask Trek AI about this page

    Chemotherapy with Acute Leukemia as Secondary Diagnosis without CC/MCC: Inpatient Reimbursement Overview

    DRG 839 categorizes inpatient admissions for chemotherapy when acute leukemia is listed as a secondary diagnosis without Complication or Comorbidity or Major Complication or Comorbidity, defining a mid-level case mix. Proper assignment affects Medicare inpatient reimbursement by grouping chemotherapy resource use apart from higher-acuity leukemia admissions with documented complications.

    Customize your policy alerts

    Sign up for drg 839 policy alerts

    Get alerted when payer policies referencing 839 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 839 Overview

    DRG 839 covers inpatient stays where the principal reason includes chemotherapy and acute leukemia is present as a secondary diagnosis without a Complication or Comorbidity or Major Complication or Comorbidity. This Diagnosis-Related Group applies to patients receiving systemic anti-neoplastic therapy during an admission and distinguishes payment when acute leukemia does not add higher complication levels. It matters for Medicare payment because it groups clinical complexity tied to chemotherapy administration separately from higher-paying categories that require documented complications. Accurate coding of the principal procedure and secondary diagnosis is central to correct assignment and reimbursement.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute inpatient supportive care intervention trials assessing strategies to reduce treatment-related complications during hospitalization for chemotherapy in patients with acute leukemia recorded as a secondary diagnosis; these studies enroll patients receiving cytotoxic or targeted chemotherapy who develop febrile neutropenia, mucositis, transfusion needs, or other acute toxicities requiring inpatient management. They evaluate interventions such as optimized antimicrobial stewardship protocols, neutropenia management pathways, blood product utilization algorithms, or standardized symptom-control bundles to shorten length of stay and reduce ICU transfers. Results are directly relevant to providers and payers because improved inpatient complication management can lower resource utilization, readmission risk, and DRG-level costs for this high-acuity cohort.
    • Comparative effectiveness and dosing strategy studies comparing chemotherapy scheduling, supportive medication timing, or anticoagulation/antiemetic regimens for hospitalized adult and older-adult patients whose principal admission is for chemotherapy with acute leukemia listed as a secondary diagnosis; these trials often use pragmatic designs in real-world inpatient settings to determine which approaches produce fewer adverse events or complications. The focus is on balancing efficacy of cancer-directed chemotherapy with minimization of hospitalization length, transfusion needs, and organ dysfunction in medically complex patients. Findings inform clinical pathways and payer coverage decisions by identifying regimens or protocols that achieve similar oncologic outcomes with lower inpatient resource consumption and complication rates.
    • Post-discharge outcomes and care-transition studies that follow patients discharged after inpatient chemotherapy with acute leukemia as a secondary diagnosis to evaluate readmission drivers, outpatient supportive care needs, and long-term functional recovery; these cohort or randomized trials test interventions such as enhanced discharge planning, outpatient neutropenia monitoring programs, or home-based nursing support. They target patients at high risk for early readmission or emergency visits due to infection, bleeding, or uncontrolled symptoms, with the goal of reducing 30-day readmissions and cumulative post-discharge costs. Payers and hospital systems use this evidence to design discharge bundles and case management policies that can decrease downstream expenditures tied to this DRG.

    Related Codes

    820-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

    Lymphoma and Leukemia with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

    821-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

    Lymphoma and Leukemia with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

    822-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

    Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

    823-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-MCC

    Lymphoma and Non-Acute Leukemia with Other Procedures with MCC: Inpatient Reimbursement Overview

    824-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-CC

    Lymphoma and Non-Acute Leukemia with Other Procedures with CC: Inpatient Reimbursement Overview

    825-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITHOUT-CC-MCC

    Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC: Inpatient Reimbursement Overview

    826-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

    827-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

    828-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

    829-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-OTHER-PROCEDURES-WITH-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

    Showing 1–10 of 27

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.